ERBB2 and breast carcinoma: A seminal work of Loi et al. indeed demonstrated that, in ER+ HER2− breast cancer, PIK3CA mutation surprisingly did not always result in elevated downstream signaling, and correlated with relatively low mTORC1 signaling [31,32].